We are thrilled to announce that EVÅQ Nano, a pioneering nanoscience company renowned for engineering innovative nanoparticles, has successfully raised $18,000,000 in its latest funding round. This remarkable injection of capital reflects strong investor confidence in EVÅQ Nanoâs multi-patented, high-volume laser nanofabrication processâa groundbreaking method that produces uniform, sub-10 nm particles with distinct surface chemistries. This technological edge not only distinguishes EVÅQ Nano in the rapidly evolving world of nanoscience but also positions the company to significantly influence the life sciences, materials, and textile industries.
The new funds will be strategically channelled into advancing products across the companyâs three core sectors. EVÅQ Bio continues to make headway with its inhaled therapeutic based on EVQ-218, a promising treatment for pulmonary bacterial infections in cystic fibrosis patients. With a successful pre-Investigational New Drug meeting with the U.S. Food and Drug Administration under its belt, EVÅQ Bio is confidently progressing toward Phase I clinical trials. Meanwhile, EVÅQ MedTech is enhancing medical devices with antimicrobial properties aimed at reducing healthcare-associated infections (HAIs), thereby potentially benefiting over one million hospital patients annually through partnerships with leading catheter manufacturers. Additionally, FUZE Technologies is expanding its footprint in the textile, hospitality, fitness, and workspace sectors with EPA-approved antimicrobial solutions that are free from chemicals, toxicity, and environmental wasteâcollaborating with top global brands such as Nike, Adidas, and Marriott, among others.
This funding milestone not only underscores the innovative spirit at the heart of EVÅQ Nano but also accelerates its mission to revolutionize healthcare, technology, and industrial applications with cutting-edge nanoscience solutions.
